KMT2D Gene Variants Identified in Immune Cell Deficiency
New research shows these variants impair natural killer cell numbers and reduce tumor destruction in human blood.
Updated on Oct. 27, 2026 in Life Sciences
Researchers have identified two previously unreported KMT2D gene variants associated with natural killer (NK) cell deficiency in humans. This research, published on October 27, 2026, details how these mutations impair immune function.
Why it matters
The findings highlight KMT2D as a critical regulator of immune surveillance, providing a clearer genetic link to impaired tumor defense. Understanding how these histone-modifying enzymes impact NK cell activity offers a new target for investigating primary immunodeficiencies.
The study identified two KMT2D variants that reduce blood NK cell counts and decrease missing-self-mediated tumor cell lysis in human cells. Comparisons with mouse models containing identical KMT2D defects confirmed a similar reduction in target cell lysis efficiency.
The details
KMT2D is a gene that encodes a histone methyltransferase, a protein that adds a methyl group to histone 3 Lys4—a chemical modification to the structural proteins that organize DNA—to regulate gene expression. By using Cas9-mediated gene editing—a molecular tool that allows for precise, directed changes to specific DNA sequences—to delete KMT2D in primary human NK cells, researchers observed that the loss of this enzyme directly impaired the cells’ ability to identify and destroy tumor targets.
Timeline
October 27, 2026: Article publication
The Tech Race
This work expands the current understanding of epigenetic regulation in the human immune system, building on broader efforts to catalog the function of histone-modifying enzymes. It sets a new benchmark for how researchers correlate rare genetic variants with functional defects in specialized immune cells.
This discovery provides diagnostic clinicians with new genetic targets to investigate in patients presenting with unexplained deficiencies in natural killer cell numbers. The findings currently exist at the research stage and do not yet offer direct clinical applications for existing patients.
The takeaway
The research confirms that KMT2D-mediated histone modification is essential for maintaining robust anti-tumor NK cell activity. Future studies will likely aim to determine whether pharmaceutical interventions targeting these epigenetic pathways can restore immune cell function in patients.
Further reading
For more on the genetic mechanisms behind immune function, explore our coverage in Life Sciences.
Source note: This article includes information reported by Nature.
